[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"polyarticular-juvenile-idiopathic-arthritis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:polyarticular-juvenile-idiopathic-arthritis":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,73],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100635532","tenosynovitis-in-polyarticular-and-oligoarticular-juvenile-idiopathic-arthritis-100635532",false,"NCT07553910","Tenosynovitis in Polyarticular and Oligoarticular Juvenile Idiopathic Arthritis","Tenosynovitis in Juvenile Idiopathic Arthritis: Insights From Polyarticular and Oligoarticular Subtypes","Inclusion Criteria:\n\n* Children and adolescents (typically under 16 years of age at the time of onset) diagnosed with Juvenile Idiopathic Arthritis (JIA).\n* Patients of both genders.\n* Patients or their legal guardians who provide written informed consent\u002Fassent to participate in the study.\n\nExclusion Criteria:\n\n* Patients more than 16 years of age.\n* Patients with arthritis secondary to other known causes (e.g., trauma, infectious arthritis, malignancy, or other systemic autoimmune diseases like Systemic Lupus Erythematosus).\n* Patients with a history of major orthopedic surgery at the examined entheseal sites.\n* Active infection or metabolic disease that may affect musculoskeletal structures.\n* Patients who decline participation or fail to provide informed consent.","ALL","16 Years",{"count":19,"type":20},106,"ESTIMATED","OBSERVATIONAL","Juvenile Idiopathic Arthritis (JIA) is a chronic condition that causes joint inflammation in children. In some cases, the inflammation also affects the protective sheath surrounding the tendons, a condition known as tenosynovitis. Because tenosynovitis can be difficult to distinguish from regular joint swelling during a standard physical exam, specialized imaging tools like ultrasound are highly useful for an accurate diagnosis.\n\nThis observational study aims to determine how frequently tenosynovitis occurs in children and adolescents diagnosed with two specific subtypes of the disease: polyarticular and oligoarticular JIA.\n\nResearchers will evaluate participants up to 16 years of age receiving care at Assiut University Children Hospital. During the study, patients will undergo a standard clinical assessment, which includes a medical history review and a thorough physical examination of their joints and tendons. Routine laboratory blood tests will also be reviewed. To precisely detect any hidden tendon inflammation, doctors will perform a musculoskeletal ultrasound, which is a safe, radiation-free imaging procedure, on major tendon and joint sites. By comparing the clinical exams with the ultrasound findings, researchers hope to improve the early recognition and management of tendon inflammation in pediatric JIA patients.",[24,25,26,27],"Juvenile Idiopathic Arthritis","Tenosynovitis","Polyarticular Juvenile Idiopathic Arthritis","Oligoarticular Juvenile Idiopathic Arthritis",[29,30,31,32,33],"Musculoskeletal Ultrasound","JIA","Pediatric Rheumatology","Enthesitis","Joint Inflammation","NOT_YET_RECRUITING","2026-04-21",{"date":37,"type":38},"2026-04-28","ACTUAL",{"date":40,"type":20},"2026-05",{"date":42,"type":20},"2027-06",{"name":44,"class":45},"Assiut University","OTHER",{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":54,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":72},"100497243","korea-xeljanz-post-marketing-surveillance-for-juvenile-idiopathic-arthritis-100497243","NCT05754710","Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis","Korean Post-marketing Surveillance for Xeljanz® 5 mg Film-coated Tablets and Xeljanz® 1 mg\u002FmL Oral Solution in Patients With Active pJIA and jPsA","KRXeljanzJIA","Inclusion Criteria:\n\nSubjects must meet all of the following inclusion criteria to be eligible for inclusion in the study:\n\n1. Pediatric subjects aged from 2 years to less than 18 years\n2. Xeljanz administered according to efficacy\u002Feffectiveness on the approved labeling\n3. Patients who will administer Xeljanz based on the medical judgement of the investigator\n4. Evidence of a personally signed and dated informed consent document indicating that the subject (and a legally acceptable representative) has been informed of all pertinent aspects of the study\n\nExclusion Criteria:\n\nSubjects meeting any of the following criteria will not be included in the study:\n\n1\\) Subjects who are contraindicated from taking Xeljanz according to approved labeling\\*\n\n\\*Refer to most recently approved label","2 Years","17 Years",{"count":57,"type":20},10,"This study is to assess the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis (JIA) patients in routine clinical practice in Korea. JIA patients experience persistent joint pain, swelling and stiffness. This is a prospective observational study.\n\nXeljanz is a JAK inhibitor. It was first approved in 2014 for rheumatoid arthritis patients in Korea. The ministry of Food and Drug Safety in Korea mandates for a drug manufacturer to report the post-marketing surveillance after drug's approval or indication extension. This study is to see the safety and effectiveness of Xeljanz in Juvenile Idiopathic Arthritis patients in routine clinical practice in Korea.\n\nThis study is seeking patients who:\n\n* Are 2 to less than 18 years of age;\n* Are given Xeljanz for the treatment of JIA.\n\nThe study sponsor will monitor patients' treatment experience for up to 44 weeks. This will help assess the safety and effects of this study medicine.",[60,26],"Psoriatic Arthritis, Juvenile","RECRUITING","2026-03-11",{"date":64,"type":38},"2026-03-13",{"date":66,"type":38},"2024-04-12",{"date":68,"type":20},"2026-09-30",{"name":70,"class":71},"Pfizer","INDUSTRY",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":83,"phases":84,"briefSummary":86,"conditions":87,"keywords":91,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":72},"100607122","phase-1-clinical-study-of-bcmacd70-targeted-car-t-therapy-for-refractory-pediatric-rheumatic-diseases-100607122","NCT07184450","Clinical Study of BCMA\u002FCD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases","Clinical Study of BCMA\u002FCD70 Targeting Chimeric Antigen Receptor T Lymphocytes(CAR-T) in the Treatment of Refractory Pediatric Rheumatic Diseases","Inclusion Criteria:\n\n* Age ≥5 years old.\n* To meet the diagnostic criteria of refractory B-cell-related pediatric rheumatic diseases, including but not limited to juvenile dermatomyositis, polyarticular juvenile idiopathic arthritis, systemic sclerosis, and primary Sjogren's syndrome.\n\n  1. Diagnosed as juvenile dermatomyositis(JDM) according to the criteria of Bohan and Peter, and meeting the following conditions:\n\n     1. The classification criteria of RJDM must meet (1) and any one of (2)-(5): (1) Patients who are intolerant or unresponsive to glucocorticoids and at least 2 immunosuppressants, and the duration of adequate hormone therapy should be at least 6 months; (2) The disease progresses rapidly and\u002For involves organs such as lungs, heart and gastrointestinal tract; (3) Calcification of subcutaneous or muscle and joint tissues; (4) Repeated rashes or skin ulcers; (5) Repeated or persistent myasthenia(muscle MRI indicates extensive, diffuse edema or the Childhood Myositis Assessment Scale(CMAS) should be less than 48 points, and at least two of the following five core measurement indicators should have abnormal results: Physician Global Assessment(PhGA) ≥2cm, Patient Global Assessment(PtGA) ≥2cm, Disease Activity Score(DAS) ≥2 points, Childhood Health Assessment Questionnaire(C-HAQ) ≥0.25 points, muscle enzyme level \\> 1.5×upper limit of normal);\n     2. RJDM with anti-synthetase syndrome who are positive for anti-synthetase antibody and those with immune-mediated necrotizing myopathy who are positive for SRP or HMGCR antibody can be included.\n  2. Meet the classification criteria for polyarticular juvenile idiopathic arthritis as defined by the International League of Associations for Rheumatology(ILAR) classification in 2001, and meeting the following conditions: After at least 6 months of traditional DMARDS treatment and at least one stable dose of DMARDS or biologic agent for ≥12 weeks, the disease is still active, that is, there are at least 2 active joints (defined as swollen joints; if there is no swelling, there must be limited passive range of motion, accompanied by pain during movement or joint tenderness).\n  3. Meet the classification criteria for Systemic sclerosis (SSc) as defined by the 2013ACR\u002FEULAR standards, and meeting the following conditions:\n\n     1. Meet the definition of intractable disease: Glucocorticoids (≥0.5mg\u002Fkg\u002Fd) and cyclophosphamide, as well as one or more of the following immunomodulators (including antimalarial drugs, azathioprine,mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, beliumab, and telitacicept, etc.), did not show significant remission of the disease for more than 3 months; Or meet the criteria for rapid disease progression , clinical routine treatment is ineffective, and the benefits outweigh the risks as determined by the investigator and the patient's or guardian's full and informed consent can be considered for inclusion;\n     2. Modified Rodnan Skin Score (mRSS) ≥15 points (total 51 points).\n  4. Meet the classification criteria for primary Sjogren's syndrome as defined by the 2002 ACEG classification criteria \u002F2016 EULAR\u002FACR classification criteria, and meeting the following conditions:\n\n     1. Meet (1) and any one of (2)-(6): (1) For those who are intolerant or have an insufficient response to glucocorticoid (prednisone 1-2 mg\u002Fkg\u002Fd or an equivalent dose of other hormones) and at least two immunosuppressants, the duration of hormone treatment should be at least 6 months; (2) The disease progresses rapidly and\u002For involves organs such as the kidneys, nervous system, and lungs; (3) Repeated parotid gland swelling or repeated parotitis; (4) Recurrent rashes or skin ulcers; (5) Involvement of the blood system, repeated leukopenia, anemia or thrombocytopenia; (6) cryoglobulinemia;\n     2. Positive for anti-SSA \u002FRo antibody;\n     3. ESSDAI score ≥5 points or clinESSDAI score ≥5 points.\n* Positive expression of CD19 in peripheral blood B cells determined by flow cytometry, and B cells \\> 5 per\u002FuL.\n* Previously not treated with CAR-T; or recurrence or poor efficacy after previous autologous or universal CD19-targeted CAR-T treatment (evaluated by the researcher).\n* The functions of important organs are basically normal:\n\n  1. Cardiac function: left ventricular ejection fraction (LVEF) ≥55%, no obvious abnormality in electrocardiogram;\n  2. Renal function: eGFR≥30mL\u002Fmin\u002F1.73m2;\n  3. Liver function: AST and ALT≤3.0 ULN, total bilirubin ≤2.0×ULN;\n  4. Lung function: SpO2≥92%.\n* Meet standards for leukapheresis or intravenous blood collection, and no other contraindications for leukapheresis.\n* The subject of childbearing age has a negative urine pregnancy test result and agrees to take effective contraceptive measures during the test period until 1 year after the infusion.\n* The patient or his\u002Fher guardian agrees to participate in this clinical trial and signs an informed consent indicating that he\u002Fshe understands the purpose and procedure of this clinical trial and is willing to participate in the study.\n\nExclusion Criteria:\n\n* Severe major organ involvement related to the primary disease, such as severe pulmonary hypertension (PHA) (mean arterial pressure \\> 45mmHg).\n* primary immunodeficiency or severe secondary immunodeficiency that has not been corrected.\n* accompanied by serious or active or uncontrollable infectious diseases, including but not limited to active tuberculosis, latent tuberculosis infection, active viral hepatitis,etc.\n* Evidence of active malignant disease or diagnosis of malignant tumor(including hematological malignancies and solid tumors, except resected and cured skin basal cell carcinoma).\n* Congenital heart disease or severe arrhythmias (including multisource frequent supraventricular tachycardia, ventricular tachycardia,etc.); Or combined with a large number of pericardial effusion, serious myocarditis, etc.;Or patients with unstable vital signs who need hypertensive drugs to maintain their blood pressure.\n* suffering from other diseases that require long-term use of glucocorticoids or immunosuppressants.\n* Received solid organ transplantation or hematopoietic stem cell transplantation within 3 months before screening; Acute graft-versushost disease (GVHD) of grade 2 or above was present within 2 weeks prior to screening.\n* Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive and peripheral blood hepatitis B virus (HBV) DNA titer greater than the normal reference value range; Or hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus (HCV) RNA titer greater than the normal reference value range; Or positive for human immunodeficiency virus (HIV) antibodies; Or syphilis test positive.\n* Had received live vaccine within 4 weeks prior to screening.\n* Positive blood pregnancy test.\n* Situations in which other investigators consider it inappropriate to participate in the study.","5 Years",{"count":82,"type":20},11,"INTERVENTIONAL",[85],"PHASE1","This is an investigator-initiated trial to evaluate the efficacy and safety of BCMA\u002FCD70-targeted CAR-T in the treatment of refractory pediatric rheumatic diseases.",[88,26,89,90],"Juvenile Dermatomyositis (JDM)","Systemic Sclerosis (SSc)","Primary Sjogren's Syndrome",[92,93],"CAR-T","BCMA\u002FCD70","2025-09-15",{"date":96,"type":38},"2025-09-19",{"date":98,"type":38},"2025-09-01",{"date":100,"type":20},"2028-09-30",{"name":102,"class":71},"Chongqing Precision Biotech Co., Ltd"]